Preventing Dengue and Navigating Vaccines
At a Glance
Preventing Dengue fever involves both mosquito control and vaccination. The Dengvaxia vaccine is strictly for those who have had Dengue before, while the Qdenga vaccine can generally be given regardless of prior infection. Always consult a doctor to determine which option is safe for you.
Preventing Dengue fever involves a two-pronged approach: reducing your exposure to the mosquitoes that carry the virus and building immunity through vaccination. While mosquito control is the traditional cornerstone of prevention, new vaccines offer powerful protection, provided they are used correctly based on your medical history [1][2].
Understanding the Two Main Vaccines
There are currently two primary vaccines used globally to prevent Dengue, but they work differently and have different safety requirements.
1. Dengvaxia (CYD-TDV)
Dengvaxia is a three-dose vaccine designed for individuals aged 9 to 45 who live in areas where Dengue is common [3].
- The Serostatus Requirement: This vaccine is only for people who have already had a Dengue infection in the past (those who are seropositive) [4][5].
- The Risk: If someone who has never had Dengue (seronegative) receives this vaccine, it acts like a “silent” first infection. If they are later bitten by an infected mosquito, their body may react as if it is a second, more dangerous infection, significantly increasing the risk of Severe Dengue and hospitalization [6][7].
- Pre-vaccination Screening: Because of this risk, the WHO and other health organizations require a blood test to confirm you have had Dengue before you can receive Dengvaxia [5][8].
2. Qdenga (TAK-003)
Qdenga is a newer, two-dose vaccine that has shown a different safety profile [9].
- Broad Use: Unlike Dengvaxia, Qdenga can generally be given to individuals regardless of whether they have had Dengue before [1][10].
- Efficacy Nuance: While highly effective and safe overall, clinical data shows Qdenga may offer slightly lower protection against certain Dengue strains (specifically DENV-3 and DENV-4) in individuals who have never had the virus before [11].
- Safety: In clinical trials, Qdenga did not show the same risk of causing more severe disease in seronegative individuals as older generation vaccines [11][12].
Mosquito Control and Personal Protection
Vaccines are powerful, but they do not replace the need for traditional prevention methods, as no vaccine is 100% effective against all types of the virus [13].
- Environmental Control: The mosquitoes that spread Dengue (Aedes aegypti) breed in clean, stagnant water. Emptying containers like flowerpots, buckets, and old tires is essential to reducing the local mosquito population [2][14].
- Personal Repellents: Use repellents containing DEET, Picaridin, or IR3535 [15]. These are the most effective at preventing bites from the day-biting Aedes mosquito [16].
- Innovative Strategies: Some regions are now using biological controls, such as releasing mosquitoes infected with Wolbachia (a bacteria that prevents the virus from growing inside the mosquito) to reduce transmission in entire cities [17][18].
Key Considerations Before Vaccination
Both vaccines are “live-attenuated,” meaning they contain a weakened version of the virus [3][9]. Because of this, they are generally not recommended for:
- Pregnant or breastfeeding women [19].
- Individuals with severely weakened immune systems (immunocompromised) [19].
Always consult with a healthcare provider to determine your serostatus and which prevention strategy is safest for your specific situation [5].
Common questions in this guide
Why do I need a blood test before getting the Dengvaxia vaccine?
What is the difference between the Dengvaxia and Qdenga vaccines?
Are Dengue vaccines safe for everyone?
What is the best way to prevent Dengue mosquito bites at home?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Am I considered 'seropositive' or 'seronegative,' and what test did you use to confirm this?
- 2.Which vaccine is currently available and recommended for me in this region?
- 3.If I take Dengvaxia as a seronegative person, what is my specific risk of severe disease if I catch Dengue later?
- 4.Does Qdenga provide equal protection against all four serotypes of the virus?
- 5.Since these are live vaccines, are they safe for me given my medical history?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (19)
- 1
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial.
Tricou V, Yu D, Reynales H, et al.
The Lancet. Global health 2024; (12(2)):e257-e270 doi:10.1016/S2214-109X(23)00522-3.
PMID: 38245116 - 2
Factors associated with mosquito control among construction workers: A systematic review.
Dapari R, Mohd Fadzil MF, Hanzir MY, et al.
PloS one 2024; (19(5)):e0303330 doi:10.1371/journal.pone.0303330.
PMID: 38718075 - 3
The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection.
Pitisuttithum P, Bouckenooghe A
Expert review of vaccines 2016; (15(7)):795-8 doi:10.1080/14760584.2016.1189331.
PMID: 27171845 - 4
Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005.
Durbin AP
Current opinion in virology 2020; (43()):79-87 doi:10.1016/j.coviro.2020.09.005.
PMID: 33164790 - 5
A cross-sectional survey to evaluate prescribers' knowledge and understanding of safety messages following Dengvaxia® product information update.
Almas MF, Toussi M, Valero E, et al.
Pharmacoepidemiology and drug safety 2022; (31(7)):758-768 doi:10.1002/pds.5447.
PMID: 35505623 - 6
Four-year safety follow-up of the tetravalent dengue vaccine CYD-TDV.
Wilder-Smith A
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2018; (24(7)):680-681 doi:10.1016/j.cmi.2018.03.024.
PMID: 29581052 - 7
Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.
Sridhar S, Luedtke A, Langevin E, et al.
The New England journal of medicine 2018; (379(4)):327-340 doi:10.1056/NEJMoa1800820.
PMID: 29897841 - 8
Risk of Dengue in Travelers: Implications for Dengue Vaccination.
Wilder-Smith A
Current infectious disease reports 2018; (20(12)):50 doi:10.1007/s11908-018-0656-3.
PMID: 30374664 - 9
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination.
López-Medina E, Biswal S, Saez-Llorens X, et al.
The Journal of infectious diseases 2022; (225(9)):1521-1532 doi:10.1093/infdis/jiaa761.
PMID: 33319249 - 10
Long term T cell response and safety of a tetravalent dengue vaccine in healthy children.
Mandaric S, Friberg H, Saez-Llorens X, et al.
NPJ vaccines 2024; (9(1)):192 doi:10.1038/s41541-024-00967-0.
PMID: 39420169 - 11
Efficacy, Immune Response, and Safety of Dengue Vaccines in Adolescents: A Systematic Review.
Naderian R, Eslami M, Ahmad S, et al.
Reviews in medical virology 2025; (35(3)):e70035 doi:10.1002/rmv.70035.
PMID: 40195054 - 12
Post-marketing safety profile of dengue vaccines CYD-TDV and TAK-003: analysis of adverse event reports from a European database.
Gianguzzo VM, Rottura M, Sacco FM, et al.
Frontiers in pharmacology 2026; (17()):1789762 doi:10.3389/fphar.2026.1789762.
PMID: 41800104 - 13
Reply to: Editorial "The increasing use of T-cell stimulation for successful dengue vaccination" in eBioMedicine 2024; 102, 105120. DOI: https://doi.org/10.1016/j.ebiom.2024.105120.
Kandeil W, Nascimento E, Tricou V, et al.
EBioMedicine 2024; (108()):105370 doi:10.1016/j.ebiom.2024.105370.
PMID: 39342806 - 14
The importance of vector control for the control and elimination of vector-borne diseases.
Wilson AL, Courtenay O, Kelly-Hope LA, et al.
PLoS neglected tropical diseases 2020; (14(1)):e0007831 doi:10.1371/journal.pntd.0007831.
PMID: 31945061 - 15
Evaluation of the efficacy of 20% IR3535® with a sustained-release formulation and 25% DEET insect repellents against mosquitoes in a field setting in Ghana.
Abudu M, Asafu-Adjaye A, Osei JHN, et al.
Parasites & vectors 2025; (18(1)):398 doi:10.1186/s13071-025-06946-1.
PMID: 41057954 - 16
Bioactivity of Linalool Against Culex quinquefasciatus: Repellent and Larvicidal Evaluations.
Kumar R, Mittal P, Airi M
Archives of insect biochemistry and physiology 2025; (120(1)):e70098 doi:10.1002/arch.70098.
PMID: 40977293 - 17
Effectiveness of Wolbachia-mediated sterility coupled with sterile insect technique to suppress adult Aedes aegypti populations in Singapore: a synthetic control study.
Bansal S, Lim JT, Chong CS, et al.
The Lancet. Planetary health 2024; (8(9)):e617-e628 doi:10.1016/S2542-5196(24)00169-4.
PMID: 39243778 - 18
Support for vector control strategies in the United States during the Zika outbreak in 2016: The role of risk perception, knowledge, and confidence in government.
Piltch-Loeb R, Merdjanoff AA, Bhanja A, Abramson DM
Preventive medicine 2019; (119()):52-57 doi:10.1016/j.ypmed.2018.12.019.
PMID: 30594531 - 19
Clinico-epidemiological determinants of severe dengue in an endemic district of coastal Karnataka.
Nivetha S, Kumar A, Eshwari K, et al.
Infectious diseases (London, England) 2025; (57(11)):1068-1077 doi:10.1080/23744235.2025.2528132.
PMID: 40650448
This page provides educational information about Dengue fever prevention and vaccines. It does not replace professional medical advice. Always consult your healthcare provider or a travel medicine specialist regarding vaccinations and your specific health needs.
Get notified when new evidence is published on Dengue fever.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.